Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours

By Kevin Robinson | Published: 23-Mar-2026
Cell & Gene Therapy

A partnership between Link Cell Therapies and CTMC is advancing next-generation CAR T therapies for solid tumours by combining dual-targeting “logic-gated” engineering with integrated manufacturing and clinical development to improve precision, safety and speed to trials

You need to be a subscriber to read this article.
Click here to find out more.

Providing treatments and cures for blood cancer patients with few other options, CAR T cell therapies have demonstrated impressive efficacy against haematological malignancies.

However, solid tumours pose a much more challenging target for this advanced class of therapies.

Expanding the benefits of CAR T cell therapies to solid tumour patients will require new approaches and an evolution of this cancer-fighting modality.

Link Cell Therapies and CTMC have come together to support the development and production of next-generation, logic-gated CAR T cell therapies engineered to target solid tumours.

Dr Kevin Robinson (KSR) sat down with Jason Bock (JB), founder and CEO of CTMC, and Jerry Cacia (JC), COO at Link Cell Therapies, to learn more about this partnership.  

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • CTMC
See more

You may also like

Cell & Gene Therapy

CTMC and Einstein Hospital Israelita form global alliance to expand access to cell therapy

Read more
The new CTMC Network Alliance will accelerate the adoption of cell and gene therapies across Latin America, aiming to make life-saving treatments more accessible through shared expertise, training and manufacturing innovation

Trending Articles

  1. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  2. Germfree and KFSHRC to bolster Saudi Arabia's influence in the cell and gene therapy space The project will expand the Kingdom's the cell and gene therapy manufacturing infrastructure, while strengthening the country's global biopharmaceutical presence
  3. Axol Bioscience expands ophthalmology portfolio with acquisition of Newcells Biotech business Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, strengthening its iPSC-derived retinal organoid and RPE model offerings
  4. Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
  5. Major breakthrough in stem cell manufacturing technology Scientists create stem cell environment that allows both self-renewal of cells and their evolution into heart cells

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Cell & Gene Therapy

CTMC and Einstein Hospital Israelita form global alliance to expand access to cell therapy

The new CTMC Network Alliance will accelerate the adoption of cell and gene therapies across Latin America, aiming to make life-saving treatments more accessible through shared expertise, training and manufacturing innovation
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Finance

Axol Bioscience expands ophthalmology portfolio with acquisition of Newcells Biotech business

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, strengthening its iPSC-derived retinal organoid and RPE model offerings
Cell & Gene Therapy

Lilly to acquire Orna Therapeutics in up to $2.4bn deal to expand in vivo CAR-T capabilities

Eli Lilly has agreed to acquire Orna Therapeutics in a deal worth up to $2.4bn, strengthening its position in in vivo cell therapies and genetic medicines targeting B cell-driven autoimmune diseases
Cell & Gene Therapy

UK ATMP clinical trials continue strong growth during 2025

The number of early-stage trials remained high, according to data from CGT Catapult, with the majority being gene therapies
Regulatory

FDA accepts first quality control standard for mesenchymal stromal cells

The FDA has accepted the first dedicated quality control protocol for mesenchymal stromal cells, recognising the Tasly 3P Characterisation Assay and setting a new regulatory benchmark for MSC safety and clinical performance
Subscribe now